Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Hepatocellular carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 6: | Line 9: | ||
**[[Esophageal adenocarcinoma]] | **[[Esophageal adenocarcinoma]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| − | |||
*[[Non-small cell lung cancer, EGFR-mutated]] | *[[Non-small cell lung cancer, EGFR-mutated]] | ||
*[[Thyroid cancer, differentiated]] | *[[Thyroid cancer, differentiated]] | ||
| Line 18: | Line 20: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
Revision as of 02:24, 19 May 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is established
Diseases for which it is used
- Esophageal cancer
- Gastric cancer
- Non-small cell lung cancer, EGFR-mutated
- Thyroid cancer, differentiated
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan